Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906640 · ClinicalTrials.gov registry record · NA
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
A NA study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 420
- Enrollment target
- 6
- Study locations
NCT06906640: Recruiting NA study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), sponsored by Duke University.
NCT06906640 is a NA study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) that is actively recruiting participants, run by Duke University. The registered enrollment target is 420 participants, below the 505-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (17% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06906640, a NA study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 420 participants
- Enrollment target
- 6
- Study locations
Study Summary
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Primary Outcome
Opportunity score of GDMT prescriptions at 6 months that were missing at baseline. The score will include prescriptions for GDMT that are active at month 6 or the loss of an indication for the GDMT.
Conditions Studied
Interventions
- OTHER (IRIS-CKD Management Program): Education
- OTHER (IRIS-CKD Management Program): GDMT
Study Locations (6)
Alabama
- University of Alabama - Birmingham
Florida
- Orlando Health - St. Petersburg
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Essentia Institute of Rural Health - Duluth
North Carolina
- Duke University - Durham
Texas
- Baylor Scott & White - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2027-04-01 |
| Phase | NA |
What NCT06906640 shows while recruiting
NCT06906640 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 505-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (17% lower).
The record links to 3 conditions, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which (IRIS-CKD Management Program): Education is the first listed.
NCT06906640 lists 6 locations in 6 states (Alabama, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT06906640 about?
NCT06906640 is a clinical study titled "Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)". IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
What is the current status of trial NCT06906640?
This trial is currently recruiting. It is a NA study. The enrollment target is 420 participants. The study started on 2025-10-28. Estimated completion is 2027-04-01.
What conditions does trial NCT06906640 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD), Type 2 DM.
What interventions are being tested in trial NCT06906640?
The interventions under investigation include: (IRIS-CKD Management Program): Education (OTHER), (IRIS-CKD Management Program): GDMT (OTHER).
Who is sponsoring clinical trial NCT06906640?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906640 being conducted?
This trial has 6 study locations across Alabama, Florida, Michigan, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06906640's enrollment target sits among peer trials
420 5th of 24 higher than 20 of 24 other Type 2 Diabetes Mellitus (T2DM) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus (T2DM) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Achieving Routine Intervention and Screening for Emotional Health
RECRUITING · NA
-
CGM for Management of Type 2 Diabetes in Pregnancy
RECRUITING · NA
-
Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED
RECRUITING · NA
-
Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
RECRUITING · NA
-
Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI